Active substance
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| DALVANCE | EQ 500MG BASE/VIAL | powder · intravenous | ABBVIE | Prescription | 23 May 2014 |
| DALBAVANCIN HYDROCHLORIDE | EQ 500MG BASE/VIAL | powder · intravenous | TEVA PHARMS INC | Prescription | 23 Oct 2025 |
| DALBAVANCIN HYDROCHLORIDE | EQ 500MG BASE/VIAL | powder · intravenous | FRESENIUS KABI USA | Prescription | 10 Nov 2025 |
| DALBAVANCIN HYDROCHLORIDE | EQ 500MG BASE/VIAL | powder · intravenous | KINDOS | Prescription | 26 Nov 2025 |
| DALBAVANCIN HYDROCHLORIDE | EQ 500MG BASE/VIAL | powder · intravenous | LONG GROVE PHARMS | Prescription | 26 Feb 2026 |
| DALBAVANCIN HYDROCHLORIDE | EQ 500MG BASE/VIAL | powder · intravenous | BE PHARMS | Prescription | 4 Jun 2026 |
Xydalba is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and paediatric patients from birth (see sections 4.4 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents.
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| XYDALBA | 02480522 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | KNIGHT THERAPEUTICS INC. |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.